Nucleoside Metabolic Inhibitor [EPC]

190958 reported adverse events

Drugs of this class: FLUOROURACIL DECITABINE CAPECITABINE AZACITIDINE CLOFARABINE CYTARABINE TRIFLURIDINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE NELARABINE

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

#	Side effect	Count
0	DIARRHOEA	17749
1	DEATH	14265
2	NAUSEA	12944
3	NEUTROPENIA	10386
4	VOMITING	10306
5	FEBRILE NEUTROPENIA	10091
6	DISEASE PROGRESSION	9381
7	FATIGUE	9301
8	PYREXIA	9079
9	THROMBOCYTOPENIA	7743

See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	143	0.8667
1	ACUTE MYELOID LEUKAEMIA RECURRENT	444	0.4336
2	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY	140	0.4094
3	PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME	5917	0.3705
4	CAECITIS	166	0.3689
5	MYELODYSPLASTIC SYNDROME TRANSFORMATION	178	0.3655
6	MYCOBACTERIUM CHELONAE INFECTION	148	0.3210
7	NEUTROPENIC COLITIS	355	0.3156
8	TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA	115	0.3059
9	DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT	273	0.2920

See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]